Stay updated on Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The record presents details of a completed Phase 2 study of pembrolizumab and bavituximab for advanced hepatocellular carcinoma, including its eligibility criteria, treatment plan, outcomes, and study documents.
    Difference
    56%
    Check dated 2026-11-08T05:35:17.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-01T02:44:55.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A banner announces an NIH website transition, links to updates and FAQs, and notes that NIH content may use both “Super Intelligence” and “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-25T02:58:52.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2. The page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-18T02:40:15.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer’s revision identifier changed from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-11T05:22:03.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden page with minimal header/footer, replacing the study details, sections, and links; users cannot view the clinical study information linked to NCT03519997.
    Difference
    20%
    Check dated 2026-09-20T02:02:34.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page.